[Translation] A randomized, open-label, single-dose, two-formulation, two-period, two-crossover bioequivalence study of isaconazole sulfate capsules in healthy subjects under fasting/postprandial administration conditions.
主要目的:考察中国健康受试者在空腹/餐后条件下单剂量口服海南通用三洋药业有限公司生产的硫酸艾沙康唑胶囊(规格:100mg)与 Pfizer Australia Pty Ltd 持证的硫酸艾沙康唑胶囊(Cresemba®/康新博®,规格:100mg)后的体内药代动力学特征,评价两制剂的生物等效性。
次要目的:评价单剂量口服硫酸艾沙康唑胶囊(规格:100mg)受试制剂及参比制剂在中国健康受试者中的安全性。
[Translation] Primary objective: To investigate the pharmacokinetic characteristics of a single oral dose of isaconazole sulfate capsules (100 mg) manufactured by Hainan General Sanyo Pharmaceutical Co., Ltd., and isaconazole sulfate capsules (Cresemba®/康新博®, 100 mg) certified by Pfizer Australia Pty Ltd in healthy Chinese subjects under fasting/postprandial conditions, and to evaluate the bioequivalence of the two formulations.
Secondary objective: To evaluate the safety of a single oral dose of isaconazole sulfate capsules (100 mg) in both the test and reference formulations in healthy Chinese subjects.